Top Stocks- Gap up, Gap Down, Active 6/15/2026 Top Stocks Up- $CUPR $CAST $VSME $AHMA Top Stocks Down- $ELTX $NMRA $CNTX $QBTZ Top Active Stocks- $PAVS $CAST $VSME $AHMA Visit for short locate and pricing and availability: speedtrader.com/stock-sellin…

Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) investorshub.advfn.com/marke…

$NMRA #fail Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update • BioPharmCatalyst biopharmcatalyst.com/company…

📉 أكثر الأسهم الأمريكية انخفاضاً اليوم 🔻 $ELTX (-71.99%) 🔻 NMRA (-47.19%) 🔻 HSPT (-31.03%) 🔻 CNTX (-28.78%) 🔻 TVAIR (-28.33%) 🔻 AIDX (-24.17%) 🔻 ATRO (-18.94%) 🔻 JVA (-17.85%) 🔻 DFNS (-17.81%) 🔻 WYHG (-17.18%) افحص شرعية أي سهم 🔗 الرابط في الملف الشخصي مسبار | فلتر #الأسهم_الأمريكية

$NMRA stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs. notreload.xyz/xy/neumora-sha…

Even the most ardent of the sell-side finally gave up on the $NMRA MOA for MDD. I admire the courage of management to use words like “best-in-class” for their other assets, without a clear trial win for the company. Pro-tip- never believe subset findings.

$NMRA tanker. bouncing

Before the opening bell, let's settle the score. Our June 10 calls on $VSME and #MSW delivered as expected, closing down 45% and 34% on day one, and losing another 18% and 7% by Friday’s close. Today's data shows the massive gap between hype and reality. #GPUS climbs 40.49% on negotiations for AI compute capacity—not a signed deal, just a conversation. Across the ticker, biotech reality hits hard. #ELTX collapses -64.31% and #NMRA dives -50.80% after their clinical trials missed primary endpoints. By contrast, #JRSH shows what a legitimate catalyst looks like, trading up 49.71% on actual earnings. Chasing hope is a highly liquid way to fund someone else’s retirement. Close the terminal and review your risk boundaries before the 9:30 AM bell rings.

Neumora Therapeutics $NMRA reports Phase 3 failure of lead asset with minimal efficacy vs placebo; program discontinued. Early-stage pipeline remains. Cash runway extends to Q3 2027. #biotech

Why Is Neumora Therapeutics $NMRA Stock Down -51% Today? $ANRO $ZNTL $IPSC $GLUE $NERV $RAPP $OVID $ALXO tickeron.com/blogs/why-is-ne…

☀️ Morning Newsletter – June 15, 2026 📈 Top up gaps: $CAST $PAVS $CUPR 📉 Top down gaps: $ELTX $NMRA $WYHG 📊 Earnings today: $WDS $AIOT $PLAY 🚀 Yesterday's movers: $CAST $SPCL $VSME #premarket #daytrading #morningnewsletter

TOP RVOL SBEV 465.2× · QUCY 462.9× · AIM 449.3× MOST ACTIVE HUT 33 · BMNR 31 · MSTU 30 MOMENTUM PAVS 136.3× · GPUS 61.6× · NIXX 60.2× TOP MOVERS NMRA 50.57% · PAVS 42.78% · SBEV 40.36% NEAR 200-EMA INTC 0.00% · ONDS 0.01% · PL 0.02%

الاسهم الدوائية أعلنت $NMRA بيانات برنامج KOASTAL للمرحلة الثالثة وقدمت تحديثاً حول أعمالها وخط أنابيبها biopharmastock.com/ar/news

$NMRA fail

I was under the impression $NMRA was now purely a play on their NLRP3 Inhibitor Program (even before today's update). Update on this in August ER. Seems a cheap bet on the hotness that is NLRP3...This is their lead asset now.

$NMRA — is scrapping its lead depression drug, navacaprant, after it failed primary endpoints in two Phase 3 studies. This is a severe pipeline setback for a primary asset. The company is taking immediate action, confirming a 35% workforce reduction designed to generate $10 million in annual cost savings. We peeled these details from the 8-K. These significant cuts, alongside an amended loan agreement, extend Neumora's cash runway into the third quarter of 2027. This provides a critical lifeline, pushing the runway out from the previous 12-month outlook into Q1/Q2 2027. While the initial drug failure hit headlines, the filing provides the hard numbers on the financial restructuring now underway. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

🔴 $NMRA — Clinical Readout Navacaprant Phase 3 KOASTAL-2 and KOASTAL-3 Fail Primary Endpoint - Development Discontinued Both KOASTAL-2 (430 patients) and KOASTAL-3 (422 patients) Phase 3 studies of navacaprant 80 mg for MDD failed to achieve statistical significance on the p…

$nmra :o Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

$NMRA - Navacaprant Phase 3 trials fail KOASTAL-2 and KOASTAL-3 missed primary endpoint for major depressive disorder. Discontinuing navacaprant program, cutting workforce by 35%.